Información del autor
Documentos disponibles escritos por este autor (3)
Añadir el resultado a su cesta Hacer una sugerencia Refinar búsqueda
texto impreso
Alcántara, Roberto ; Fuentes, Patricia ; Marin, Lisette ; Kirwan, Daniela E. ; Gilman, Robert H. ; Zimic, Mirko ; Sheen, Patricia | American Society for Microbiology | 2020-07-14T00:00:54ZPyrazinamide (PZA) is considered the pivot drug in all tuberculosis treatment regimens, due to its particular action on the persistent forms of Mycobacterium tuberculosis. However, no drug susceptibility test (DST) is considered sufficiently rel[...]texto impreso
Alcántara, Roberto ; Fuentes, Patricia ; Antiparra, Ricardo ; Santos, Marco ; Gilman, Robert H. ; Kirwan, Daniela E. ; Zimic, Mirko ; Sheen, Patricia | American Society for Microbiology | 2018-11-30T17:17:15ZAlthough pyrazinamide (PZA) is a key component of first and second line tuberculosis treatment regimens, there is no gold standard to determine PZA resistance. Approximately 50% of multidrug-resistant tuberculosis (MDR-TB) and over 90% of extens[...]texto impreso
Rueda, Daniel ; Furukawa, Roberto ; Fuentes, Patricia ; Comina, Germán ; Rey De Castro, Nicolás G. ; Requena, David ; Gilman, Robert H. ; Sheen, Patricia ; Zimic, Mirko | Medknow Publications | 2018-11-30T02:09:28ZIntroduction: Tuberculosis (TB) is a significant cause of morbidity and mortality worldwide. The patient compliance with the long treatment regimens is essential for successful eradication. Pyrazinamide (PZA) shortens these regimens from 9 to 6 [...]
